RE:RE:Merck in advanced talks to buy Seagen in nearly $40-bln deal You'd say we're worth half of Seagen?
See, it's posts like this that convince me that Big Pharma has agents posting here to convince investors to sell out cheap.
We are worth at least four times Seagen.
We have the cure for cancer in clinical trials, the cure for emergent viruses pending, AND an anti-cancer vaccine showing promise, as more and more data on post-treatment immunity becomes available.
Dude, you don't sell the biggest life-sciences breakthrough in the history of medecine to Big Pharma.
You set up your own Pharma-Tech corporation, and buy up the failing Big Pharmas!
Stop lowballing on these boards. GLTA real investors!
ScienceFirst wrote: So Merck has devoted its future on SEAGEN, to replace Keytruda as its main revenue driver. Now, imagine a Merck competitor buying us (ltes say for half of that amount) and deploying its resources to advance our family of PDCs in different indications to deliver high efficacy and then capture higher market shares for each of these markets:
Cancer drug Keytruda, set to lose exclusivity in 2028, generated sales of $17.2 billion in 2021 and accounted for 35.2% of Merck's total revenue.
It makes sense if Merck can close the deal at $250 or below (46B$US) as the acquisition will help the drugmaker fortify its portfolio ahead of top money-spinner Keytruda losing its marketing exclusivity, Wells Fargo analyst Mohit Bansal said.
Seagen has several clinical-stage oncology candidates, as well as four approved drugs including breast cancer therapy Tukysa, which together brought in more than $1 billion in revenue last year.
The acquisition talks come at a time when several big corporate deals have been shelved as a downturn in equity markets hurts company valuations, while rising borrowing costs make deal financing costlier and harder to access.
Bansal, however, said Merck's balance sheet capacity would not be an issue for the deal.